Antibody/Targeted-Drug Conjugates 2017

22-24 March 2017, Leiden University Medical Centre, Leiden, The Netherlands

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Friday 24th March 2017

SESSION 9:
DEVELOPMENT

Moderator: Christopher Scott (Queen’s University of Belfast, Belfast, Northern Ireland, UK)

09.00-09.45
‘Development of nano-conjugates as novel therapeutics’

Christopher Scott (Queen’s University of Belfast, Belfast, Northern Ireland, UK)

09.45-10.15
‘Manufacturing of SYD985, a duocarmycin-based ADC’

Aad van de Leur (Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands)

10.15-10.45
‘Optimized methods for site-specific antibody drug conjugations avoiding cross-linked byproducts’

Amy Han (Regeneron Inc., Tarrytown, New York, USA)

10.45-11.15
‘Scaling-up and manufacturing antibody-drug conjugates’
Laurent Ducry (Lonza AG, Visp, Switzerland)

11.15-11.30
Coffee Break & Posters

SESSION 10:
ANTIBODY DRUG CONJUGATES

Moderator: Hendrick Jan Houthoff (LinXis Pharmaceuticals, Amsterdam, The Netherlands)

11.30-12.00
‘TG-IPH Technology for site-specific conjugation’
Delphine Bregeon and Florence L’Hospice (Innate-Pharma S.A. Marseille, France)

12.00-12.15
POSTER 101

‘Site-specific and quantitative conjugation of functional groups to antibody N-glycans using the novel GlyCLICK technology’
H. Toftevall1, H. Nyhlén1, M. Widgren Sandberg1, B. Agnew2 and F. Olsson1 (1 Genovis AB, Lund, Sweden; 2 Thermo Fisher Scientific, Eugene, Oregon, USA)

12.15-12.30
POSTER 102

‘Chemical cross-linking strategies for the construction of homogeneous protein bioconjugates’
Nafsika Forte, Kerry Chester, Vijay Chudasama and James Baker (UCL Chemistry Department, London, UK; UCL Cancer Institute, London, UK)

12.30-12.45
POSTER 103

‘Pyridazinediones: Highly versatile chemical linkers for bioconjugation’
Daniel A. Richards1, Antoine Maruani1, Maximillian T. Lee1, Joao C. F. Nogueira1, Michelle Greene2, Christopher Scott2 and Vijay Chudasama1 (1 University College London, London, UK; 2 Queen’s University Belfast, Belfast, Northern Ireland, UK)

12.45-13.00
POSTER 104
‘Dual site-specifically modified antibodies using solid-phase immobilized microbial transglutaminase’
Philipp R. Spycher1, Christian A. Amann1, Jöri E. Wehrmüller1, David R. Hurwitz1, Olivier Kreis1, Daniel Messmer2, Andreas Ritler1,3, Andreas Küchler2, Alain Blanc1, Martin Behé1, Peter Walde2 and Roger Schibli1,4
( 1 Paul Scherrer Institute, Villigen PSI, Switzerland; 2 Laboratory of Polymer Chemistry, Department of Materials, 3 Laboratory of Organic Chemistry and 4 Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland)

Lunch Break & Departure

POSTER 105
‘Antibody Drug Conjugates for gynaecological cancers’
Belen Pan Castillo, R. Steve Conlan and Deyarina Gonzalez (Swansea University Medical School, Swansea University, Swansea, Wales, UK)

* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

 

ATDC 2017 Delegates

Login details will be supplied after you have registered for the event.


ATDC 2017 Sponsors

  • ONdrugDelivery
  • Sutro BioPharma
  • ADC Review
  • NatureGeneTherapy.com
  • Oncozine
  • Genentech
  • Lonza
  • LinXis
  • Catalent
  • ImmunoGen
  • NBE Therapeutics
  • Pfizer Oncology
  • Aldevron
  • Cancer Targeting Solutions Consultancy
  • Genovis

ATDC 2017 Downloads

ATDC 2017 Leaflet

ATDC 2017 Mailing List

Name
E-mail Address
What is 3+2-1?